29th week of 2013 patent applcation highlights part 43 |
Patent application number | Title | Published |
20130184225 | ROMIDEPSIN FORMULATIONS AND USES THEREOF - Provided herein are formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation is a combination of romidepsin and mannitol. | 2013-07-18 |
20130184226 | MODULATIONS OF PROTEASE ACTIVATED RECEPTORS - The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity. | 2013-07-18 |
20130184227 | Cytochrome P450 2C9 Inhibitors - This invention is to provide multiple specific inhibitors of cytochrome P450 isozyme CYP2C9. These inhibitors can be derived from any combinations with the following compounds including: Tamarixetin, Formononetin, isoliquritigenin, Phloretin, luteolin, Quercitrin, quercetin, myricetin, Wongonin, Puerarin, Genistein, Nordihydroguaiaretic acid, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, 6-Gingerol, Isorhamneti, isoquercitrin, Morin, (+)-Taxifolin, isovitexin, 3-Phenylpropyl Acetate, Oleanolic acid, ursolic acid, β-Myrcene, cinnamic acid, Luteolin-7-Glucoside, Liquiritin, (+) Limonene, Homoorientin, Swertiamarin, Embelin, Daidzein, Poncirin, (−)-Epicatechin, ergosterol. These natural products can be used to enhance the bioavailability of therapeutic agents (drugs). | 2013-07-18 |
20130184228 | MUSCADINE COMPOSITIONS WITH ANTI-OXIDANT ACTIVITY - Antioxidant compositions are disclosed that include muscadine pomace extract and resveratrol from a source other than muscadine. In other examples the composition also includes polyphenols from a source other than muscadine. The compositions increase the expression of antioxidant genes and/or genes associated with mitochondrial biogenesis. | 2013-07-18 |
20130184229 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS - Compounds, compositions and methods are provided for treating cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood. More specifically, heterobifunctional compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described. | 2013-07-18 |
20130184230 | COMBINATION OF A PYRROLOQUINOLINE COMPOUND AND A BETA-LACTAM ANTIMICROBIAL AGENT, MUPIROCIN OR CHLORHEXIDINE - This invention relates to the use of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof in combination with another antimicrobial agent selected from the group consisting of a beta-lactam antimicrobial agent, mupirocin and chlorhexidine or a pharmaceutically acceptable derivative thereof, for the prevention and/or treatment of microbial infections. | 2013-07-18 |
20130184231 | ORGAN ARREST, PROTECTION AND PRESERVATION - The present invention relates to a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) local anaesthetic to a subject in need thereof. | 2013-07-18 |
20130184232 | METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS - Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient. | 2013-07-18 |
20130184233 | Personal Lubricant Compositions - A skin lubrication lotion that functions as a skin rubbing anti-friction barrier compound to prevent skin rashes from burning of skin from excessive rubbing, said lotion comprising: a lubricant; a skin numbing ingredient including lidocane; a vitamin ingredient, wherein the vitamin is selected from the group consisting of vitamin A, C, E, D or B 12; an ingredient that causes human skin to tingle, wherein the tingling ingredient is selected from the group consisting of menthol and L-arginine ethyl ester; wherein the skin lotion further consisting essentially of about: 71% water, 0.070% sodium benzoate, 0.070% potassium Sorbate, 0.180% citric acidanhydrous (FCC, USP), 14.200% glycerine 99.7%, 14.200% propylene glycol USP, 0.140% Xanthan gun 80 mesh, and 0.140% guar gun 250 (food grade). | 2013-07-18 |
20130184234 | BIOMATERIALS CONSISTING OF SULPHATED HYALURONIC ACID AND GELLAN TO BE USED IN THE PREVENTION OF SPINAL ADHESIONS - New biomaterials consisting of a combination of sulphated hyaluronic acid and gellan (as well as gellan that has not been associated with other polymers), to be used as a highly effective barrier to prevent post-surgical adhesions in abdominal, pelvic and, above all, spine surgery. | 2013-07-18 |
20130184235 | HYALURONIC ACID DERIVATIVES CONTAINING GROUPS ABLE TO RELEASE NO - Disclosed are hyaluronic acid derivatives functionalised with S-nitrosothiol groups of the general formula: wherein HA indicates hyaluronic acid and G indicates a suitable spacer. | 2013-07-18 |
20130184236 | COMPOUND HAVING DETRUSOR MUSCLE-CONTRACTING ACTIVITY AND URETHRAL SPHINCTER MUSCLE-RELAXING ACTIVITY - Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and/or ameliorating underactive bladder. | 2013-07-18 |
20130184237 | NITRIC OXIDE DELIVERING HYDROXYALKYL STARCH DERIVATIVES - The present invention relates to nitric oxide delivering hydroxyalkyl starch derivatives, methods of preparing the same, and specific uses of these hydroxyalkyl starch derivatives. | 2013-07-18 |
20130184238 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY - The present invention relates to aminotetraline derivatives of the formula (I) | 2013-07-18 |
20130184239 | COMBINATION OF SILOXANE AND ACTIVE INGREDIENT FOR TREATING DENTAL DISORDER - The invention relates to a pharmaceutical composition comprising a siloxane according to general formula (I)< | 2013-07-18 |
20130184240 | HETERO RING-FUSED IMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT - Disclosed is a compound which is useful as an AMPK activator. A compound represented by the formula: | 2013-07-18 |
20130184241 | Naphthalene Derivative - The present invention provides compounds which can regulate VCP activity. The present invention provides the compound of formula (I) | 2013-07-18 |
20130184242 | Pharmaceutical Composition for Topical Application - A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance. | 2013-07-18 |
20130184243 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH - Provided are compositions comprising alkylating agents, including nitrogen mustards, that are suitable for topical use, and methods for treating skin disorders comprising topically administering the compositions. | 2013-07-18 |
20130184244 | PROCESS FOR PREPARING DELTA-7,9(11) STEROIDS FROM GANODERMA LUCIDUM AND ANALOGS THEREOF - Processes for preparing lanostane triterpenes from the medicinal mushroom | 2013-07-18 |
20130184245 | ENDOMETRIOSIS TREATMENT - A pharmaceutical composition comprises at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to a vaginal mucosal surface, and comprises danazol in an amount of about 3% to about 30% by weight of the composition, wherein upon application of the composition to the vaginal mucosal surface the danazol is released over a period of about 1 to about 10 days. The composition is useful for intravaginal administration to treat a condition such as endometriosis for which danazol is indicated. | 2013-07-18 |
20130184246 | METHOD FOR TREATING FATTY LIVER DISEASES, IN PARTICULAR NON-ALCOHOLIC STEATOHEPATITIS - The invention is in the field of medical treatments of liver disease, in particular, non-alcoholic fatty liver diseases, such as non-alcoholic steatohepatitis. The invention provides a composition comprising an effective amount of a compound capable of increasing the intracellular level of 27-hydroxycholesterol for the treatment of liver inflammation in fatty liver disease. It also provides a method of reducing liver inflammation in a patient with non-alcoholic fatty liver disease by administering an effective amount of 27-hydroxycholesterol. | 2013-07-18 |
20130184247 | METHOD FOR PREPARATION OF NICOTINIC ACID COPPER CHLORIDE COMPLEX, AND ITS PHARMACEUTICAL USES - A method for preparation pharmaceutical compounds in large quantities consists of copper (I) halide, preferably the chloride complex of nicotinic acid characterized by elemental analysis, spectroscopy and crystallographic methods, used for treatment of muscular dystrophy, myopathy, myasthenia gravis, parkinsonism, Chronic Fatigue Syndrome, Male Infertility and post stroke muscle weakness. | 2013-07-18 |
20130184248 | NOVEL COMPOUNDS - This invention relates to compounds of formula I | 2013-07-18 |
20130184249 | PYRROLIDINE DERIVATIVES - The present invention relates to compounds of formula | 2013-07-18 |
20130184250 | Therapeutic Agents - Disclosed herein are azetidinyl compounds of formula I, | 2013-07-18 |
20130184251 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS - Disclosed are compounds, compositions and methods for treating diseases, syndromes, conditions and disorders that are affected by the inhibition of MGL, including pain. Such compounds are represented by Formula (I) as follows: | 2013-07-18 |
20130184252 | DIHYDROPYRROLONAPHTHYRIDINONE COMPOUNDS AS INHIBITORS OF JAK - Disclosed are JAK inhibitors of formula I | 2013-07-18 |
20130184253 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS - The present invention provides a compound of formula I: | 2013-07-18 |
20130184254 | AZAINDAZOLE COMPOUNDS - Disclosed are azaindazole compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein W is CR | 2013-07-18 |
20130184255 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 2013-07-18 |
20130184256 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS - The present invention relates to new substituted glycinamides of general formula (I) | 2013-07-18 |
20130184257 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS - Compounds of Formula (I) and pharmaceutically acceptable salts thereof in which X | 2013-07-18 |
20130184258 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels - The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 2013-07-18 |
20130184259 | PYRIDONES USEFUL AS INHIBITORS OF KINASES - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing the compounds of the invention and intermediate compounds useful in these processes. | 2013-07-18 |
20130184260 | PYRIDAZINONE DERIVATIVES - Compounds of the formula (I), in which R | 2013-07-18 |
20130184261 | PYRIDAZINONE DERIVATIVES - Compounds of the formula (I), in which R | 2013-07-18 |
20130184262 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF - The present invention provides compounds of Formula (I): | 2013-07-18 |
20130184263 | Derivatives of Betulin - The present invention relates to compounds characterized by having a structure according to the following Formula I: | 2013-07-18 |
20130184264 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders - The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a BET family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone N-terminal tail). | 2013-07-18 |
20130184265 | Prodrugs of Secondary Amine Compounds - The present invention relates to compounds of Formula I: | 2013-07-18 |
20130184266 | HETEROCYCLIC COMPOUND AND USE THEREOF - Provided is a compound represented by the formula (I): | 2013-07-18 |
20130184267 | Antimicrobial Compositions and Methods of Use - In one aspect, compositions provide antimicrobial therapy as topical disinfectants. Particularly, one aspect relates to an alcohol containing antimicrobial composition that includes at least one paraben, a redox compound and an organic acid at a concentration of from about 1.5 percent to about 10 percent by weight, based on the total weight of the composition. In other aspects, antimicrobial compositions are used to topically sanitize wounds, skin areas and/or to disinfect surgical instruments or other surfaces. Still, in further aspects, methods, devices and kits relating to an antimicrobial composition are provided. | 2013-07-18 |
20130184268 | 2-(R2-THIO)-10-[3-(4-R1-PIPERAZIN-1-YL) PROPYL]-10H-PHENOTHIAZINE FOR TREATING A BETA-AMYLOIDOPATHY OR AN ALPHA-SYNUCLEOPATHY, AND METHOD FOR THE DIAGNOSIS OR PREDIAGNOSIS THEREOF - The invention relates to 2-(R | 2013-07-18 |
20130184269 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE - This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic[4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2013-07-18 |
20130184270 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS - The present invention relates to: combinations of: component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; component B: one or more N-(2-arylamino)aryl sulfonamide compounds of general formula (B), or Lapatinib, or Paclitaxel, or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; and, optionally, component C: one or more further pharmaceutical agents; in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially. dependently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route; use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer; and a kit comprising such a combination. | 2013-07-18 |
20130184271 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds - This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like. | 2013-07-18 |
20130184272 | DIABETES THERAPEUTIC AGENT - The problem of the present invention is to provide a compound useful for the prophylaxis or treatment of diseases related to the control of the differentiation of muscle cell or adipocyte differentiation, such as diabetes, obesity, dyslipidemia, and having a superior efficacy. | 2013-07-18 |
20130184273 | BICYCLIC PYRIMIDINES - Compounds of formula (I), which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals. | 2013-07-18 |
20130184274 | Protein Kinase Inhibitors and Methods of Treatment - The present invention relates to chemical compounds of formula (I) and methods for their use and preparation. In particular, the invention relates to substituted pyrazolo[3,4-d]pyrimidine based compounds which can be used in treating proliferative disorders, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds. | 2013-07-18 |
20130184275 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS - Hydrazone compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein. | 2013-07-18 |
20130184276 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2013-07-18 |
20130184277 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME - The present invention provides adamantyl diamide derivatives of formula (I): | 2013-07-18 |
20130184278 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 2013-07-18 |
20130184279 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES - Compounds of formula Ia and Ib | 2013-07-18 |
20130184280 | SUBSTITUTED THIAZOLES AS VEGFR2 KINASE INHIBITORS - Disclosed herein are substituted thiazoles and their salts that are VEGFR2 kinase inhibitors, useful in the treatment of cancer. | 2013-07-18 |
20130184281 | USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE, SECONDARY ISCHEMIA, AND DISORDERS ASSOCIATED WITH AN INCREASED LEVEL OF CYTOTOXIC REACTIVE OXYGEN SPECIES - The present invention relates to the use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species. | 2013-07-18 |
20130184282 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS - The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. | 2013-07-18 |
20130184283 | METHOD FOR TREATING PSORIASIS - Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an α2 adrenergic receptor agonist. | 2013-07-18 |
20130184284 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF - The present invention provides compounds of Formula (I): | 2013-07-18 |
20130184285 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES - The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein. | 2013-07-18 |
20130184286 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS - This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologically active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors. | 2013-07-18 |
20130184287 | INDAZOLE COMPOUNDS AND THEIR USES - The present application relates to therapeutic organic compounds, compositions comprising an effective amount of a therapeutic organic compound; and methods for treating and preventing disease comprising administering and effective amount of a therapeutic organic compound to a subject in need thereof. | 2013-07-18 |
20130184288 | Aminooxazole Inhibitors of Cyclin Dependent Kinases - Oxazole derivatives are described. The inventive compounds are useful as kinase inhibitors, and may be used in the treatment of cancer, such as prostate cancer, lung cancer, breast cancer, colon cancer, leukemia, CNS cancer, melanoma, ovarian cancer, and renal cancer. | 2013-07-18 |
20130184289 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES - Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists. | 2013-07-18 |
20130184290 | SELF-EMULSIFYING FORMULATIONS AND METHODS OF USE THEREOF - The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more self-emulsifying carriers. | 2013-07-18 |
20130184291 | THERAPEUTIC USES OF 1-[2-(2,4-DIMETHYL-PHENYLSUFLANYL)PHENYL]PIPERAZINE - The invention provides new therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]-piperazine and pharmaceutically acceptable salts thereof. | 2013-07-18 |
20130184292 | Processes for Making Compounds Useful as Inhibitors of ATR Kinase - The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. | 2013-07-18 |
20130184293 | COMPOSITIONS AND METHODS FOR TREATING DIABETES AND NEUROPSYCHOLOGICAL DYSFUNCTION - The present invention relates to compositions and methods for treating diabetes mellitus, neuropsychological and neurological disorders in a particular group of patient. More specifically, the invention relates to methods of treating diabetes mellitus, neuropsychological and neurological disorders in patients having defective potassium channels. The invention may be used in human subjects, particularly adults or children, and is appropriate to treat various neurological disorders. | 2013-07-18 |
20130184294 | Pyrimidones for Treatment of Potassium Channel Related Diseases - The present invention relates to compounds of Formula I as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and methods of treating a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogenital disorders, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient. | 2013-07-18 |
20130184295 | METHOD OF IDENTIFYING THERAPIES FOR PULMONARY HYPERTENSION - The present invention is directed to a method of screening for a therapeutic agent useful for treating pulmonary hypertension comprising: contacting an erythrocyte with a candidate therapeutic agent; and detecting a presence or absence of erythrocyte-derived adenosine triphosphate, wherein a greater erythrocyte-derived adenosine triphosphate level indicates the candidate therapeutic agent has greater activity in treating pulmonary hypertension. Additionally, the present invention is directed to methods of treating pulmonary arterial hypertension by stimulating ATP release from erythrocytes through co-administration to a subject in need thereof an amount of a PDE5 inhibitor compound, and an amount of a prostacyclin compound. | 2013-07-18 |
20130184296 | PARENTERAL SOLUTIONS CONTAINING METOLAZONE - Disclosed herein are parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamide in N,N-dimethylacetamide, polyethylene glycol and D | 2013-07-18 |
20130184297 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF - The invention relates to quinazoline derivatives substituted by aniline which are represented by the below formula (I), pharmaceutical acceptable salts and stereoisomer thereof, wherein these groups of R | 2013-07-18 |
20130184298 | DIHYDROBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to dihydrobenzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 2013-07-18 |
20130184299 | CCR2 ANTAGONISTS AND USES THEREOF - The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. | 2013-07-18 |
20130184300 | Methods of Treating Traumatic Brain Injury Using Pro-Neurogenic Compounds - This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death. | 2013-07-18 |
20130184301 | Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds - This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death. | 2013-07-18 |
20130184302 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) AND INFECTIONS - The present invention provides new methods and kits for the retreatment of IBS, for reducing commonly-occurring infections in patients suffering from hepatic encephalopathy, and for reducing frequency of incidence of | 2013-07-18 |
20130184303 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE - This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2013-07-18 |
20130184304 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE - This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2013-07-18 |
20130184305 | PROCESS FOR PREPARATION OF NOVEL 42-O-(HETEROALKOXYALKYL) RAPAMICIN COMPOUNDS WITH ANTI-PROLIFERATIVE PROPERTIES - The invention discloses novel 42-0-(heteroalkoxyalkyl) rapamycin compounds of formula (1) and process for preparation thereof. These compounds are useful in the treatment of hyperproliferative vascular diseases such as restenosis and atherosclerosis Wherein, R denotes 3, 4 and 5 membered 3-hydroxy heteroalkoxyalkyl compounds selected from Tetrahydrofuran-3-ol, Oxetan-3-ol, Tetrahydropyran-3-ol, Tetrahydro-4- methyl furan-3-ol, Tetrahydro-2,5,5-trimethyl furan-3-ol, Tetrahydro-2,5-diethyl-2-methyl furan-3-ol, Tetrahydro-6-methoxy-2-methyl 2H-Pyran-3-ol and Tetrahydro-2,2-dimethyl-6-phenyl 2H-Pyran-3-ol. | 2013-07-18 |
20130184306 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE - This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2013-07-18 |
20130184307 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS - The present invention relates to certain substituted tricyclic acid derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. | 2013-07-18 |
20130184308 | ACTIVATED BLOOD COAGULATION FACTOR X (FXa) INHIBITOR - An object of the present invention is to provide an activated blood coagulation factor X (FXa) inhibitor that reduces the risk of bleeding caused by the treatment of thromboembolism. The present invention provides an oral anticoagulant agent comprising a compound represented by the following formula ( | 2013-07-18 |
20130184309 | METALLOENZYME INHIBITOR COMPOUNDS - The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes. | 2013-07-18 |
20130184310 | TREATMENT OF LUPUS ARTHRITIS USING LAQUINIMOD - This invention provides a method of treating a subject afflicted with active lupus arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus arthritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with lupus arthritis. | 2013-07-18 |
20130184311 | CRYSTALLINE FORMS OF THE SODIUM SALT OF (4--CYCLOHEXYL)-ACETIC ACID - The present invention relates to novel crystalline forms of (4-{4-[5-(6-Trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, sodium and their use in the treatment or prevention of a condition or a disorder associated with DGAT1 activity in animals, particularly humans. It also relates to processes for making such novel crystalline forms. | 2013-07-18 |
20130184312 | Tetomilast Polymorphs - The present invention provides a tetomilast crystal that is industrially easily produced in a large volume. (1) a tetomilast hydrate crystal having a power X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in FIG. | 2013-07-18 |
20130184313 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF - The invention relates to pyridinyl nicotinic acetylcholine receptor ligands, compositions comprising an effective amount of a pyridinyl nicotinic acetylcholine receptor ligand and methods to treat or prevent a condition, such as depression and nicotine dependence, comprising administering to an animal in need thereof an effective amount of a pyridinyl nicotinic acetylcholine receptor ligand. | 2013-07-18 |
20130184314 | Novel Phenylamino Isonicotinamide Compounds - The invention provides novel compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. | 2013-07-18 |
20130184315 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR - Compounds of formula (I) and formula (II) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 2013-07-18 |
20130184316 | METHODS FOR DIAGNOSING AND TREATING CONCUSSIVE DISORDERS - The invention provides methods for treating, suppressing, ameliorating and/or preventing the effects of disorders relating to concussion, including those associated with post-concussion syndrome. The methods comprise administering to a subject an effective amount of a compound that modulates neuronal ion channel function, or a pharmaceutically acceptable salt, solvate or hydrate thereof, or a composition comprising a compound that modulates neuronal ion channel function, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a pharmaceutically acceptable carrier. The invention also provides inventive methods relating to identifying, classifying and/or diagnosing conditions involving post-concussion syndrome and related concussive disorders. | 2013-07-18 |
20130184317 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME - Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein. | 2013-07-18 |
20130184318 | MODULATING COMPLIANCE OF TRABECULAR MESHWORK - The present invention provides methods of determining the effect of test agents on the compliance of trabecular meshwork (TM) tissue, at the level of the extracellular matrix (ECM) and/or cells within the TM. Agents that modulate (e.g., increase or decrease) compliance of the TM tissue find use. Agents that increase the compliance of ECM and TM cells within the TM find use in the treatment and prevention of eye disorders characterized by high intraocular pressure, e.g., glaucoma. | 2013-07-18 |
20130184319 | FUNGICIDAL ACTIVE SUBSTANCE COMBINATIONS - The invention relates to novel fungicidally active compound combinations of 2′-cyano-3,4-dichloroisothiazole-5-carboxanilide and active compounds listed in the disclosure. | 2013-07-18 |
20130184320 | Imine Compounds - The present invention relates to imine compounds which are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds. | 2013-07-18 |
20130184321 | Model Mouse of Attention Deficit Hyperactivity Disorder, Method for Investigating Effects for Preventing and Alleviating Attention Disorder using the Model Mouse, and Method for Treating Attention Disorder by Suppressing T-Type Calcium Channel - The present invention relates to an Attention deficit and hyperactivity disorder (ADHD) mouse model and a screening method for a composition for the prevention and treatment of attention deficit disease. The mouse model constructed by inserting cobalt wire in the right side of the frontal lobe is very useful as the ADHD mouse model, and the said ADHD mouse model can be effectively used for the screening of an agent for the treatment of attention deficit disease since the mouse demonstrated brain wave with low frequency, hyperactivity, and cognitive impairment, which are characteristic symptoms of attention deficit disease, when ethosuximide, one of T-type calcium channel blockers, was administered. Therefore, the composition comprising a T-type calcium channel blocker was also confirmed to be effectively used for the prevention and treatment of attention deficit disease. | 2013-07-18 |
20130184322 | NOVEL DIPEPTIDYL-PEPTIDASE-IV INHIBITORS - The invention comprises novel inhibitors of dipeptidyl peptidase IV (DPP-IV) with beta blocker activity, pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP-IV, and novel methods of treating medical conditions are provided. The novel inhibitors of DPP-IV described herein are useful in the treatment of neurological disorders, diabetes, inflammatory disorders such as arthritis, obesity, osteoporosis, hypertension, and glaucoma of such other enumerated conditions as can be treated with inhibitors of DPP-IV and beta blockers. | 2013-07-18 |
20130184323 | TREATMENT OF ENDOPLASMIC RETICULUM STRESS-RELATED DISEASES AND CONDITIONS - A method of treating a disease or condition associated with at least one of a cellular accumulation of unfolded and/or misfolded proteins, an abnormal unfolded protein response (UPR), an endoplasmic reticulum (ER) stress, and an abnormal autophagy response, is disclosed. The method may include administering one or more flexible heteroarotinoid compounds which target, bind to, disrupt, and/ or modulate the activity of one or more of heat shock proteins | 2013-07-18 |
20130184324 | Dual Targeting siRNA Agents - The invention relates to dual targeting siRNA agents targeting a PCSK9 gene and a second gene, and methods of using dual targeting siRNA agents to inhibit expression of PCSK.9 and to treat PCSK.9 related disorders, e.g., hyperlipidemia. | 2013-07-18 |